Trending...
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling
- DeployHub Joins Catalyst Campus SDA TAP Lab
First and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventative action and improve outcomes.
LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.
NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.
More on Ohio Pen
"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."
Journey Biosciences received CLIA certification for its lab in August 2022 and all NaviDKD blood samples are processed in this Cleveland, Ohio-based lab.
Both healthcare professionals and people with diabetes can learn more and request NaviDKD at www.journeybio.life.
More on Ohio Pen
About Journey Biosciences
Journey Biosciences is a US-based biotechnology company dedicated to fundamentally improving diabetes care. We are focused on identifying blood-based predictive biomarkers and developing clinically validated, laboratory developed tests (LDTs) that identify and rate a person's risk level for developing complications from diabetes. Learn more at www.journeybio.life.
Know Your Risk. Change Your Life. ™
To access the Journey Biosciences media kit, visit journeybio.life/media
SOURCE Journey Biosciences, Inc.
LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.
NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.
More on Ohio Pen
- Americans Are Trading Offices for Beaches: How Business Ownership Enables the Ultimate Location Freedom
- Boston Industrial Solutions' Natron® DC Series Ink Has Had an Upgrade!
- Colony Ridge Proudly Supports the All Ears! 2025 Sporting Clays Tournament
- Jacob Emrani Nominated for LA Executive Award
- Kansas City Steak Company Shares the Return of Their Holiday Gift Box
"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."
Journey Biosciences received CLIA certification for its lab in August 2022 and all NaviDKD blood samples are processed in this Cleveland, Ohio-based lab.
Both healthcare professionals and people with diabetes can learn more and request NaviDKD at www.journeybio.life.
More on Ohio Pen
- The Simple Portrait {project} aka TSPp : A Cincinnati exclusive portrait event running NOV 5-DEC 8
- Dr. Jay A. Johannigman Delivers Lecture at the John R. Border Memorial Lectureship in Buffalo
- Powering the Next Frontier of the $1 Trillion Space Economy: Ascent Solar Technologies (N A S D A Q: ASTI)
- Taikan's T-V856S VMC Earns Prestigious 2025 Vogel Global Pioneer Award
- Flick Truck Accident Law Joins the Commercial Vehicle Safety Alliance to Strengthen Truck Safety Advocacy
About Journey Biosciences
Journey Biosciences is a US-based biotechnology company dedicated to fundamentally improving diabetes care. We are focused on identifying blood-based predictive biomarkers and developing clinically validated, laboratory developed tests (LDTs) that identify and rate a person's risk level for developing complications from diabetes. Learn more at www.journeybio.life.
Know Your Risk. Change Your Life. ™
To access the Journey Biosciences media kit, visit journeybio.life/media
SOURCE Journey Biosciences, Inc.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Bestselling Author Returns Home for Toledo Romance Con
- American Star Guard Unveils a Powerful Rebrand and Expanded Security Services Throughout Nevada
- PlaceBased Media Expands Point-of-Care Advertising Inventory Across U.S. Clinic Network
- Flexible Plan Investments launches FlexDirex, a first-to-market suite of single-stock ETF strategies in the U.S
- Artsman Brings the 2025 Florida Gators National Championship Court to Life for Fans
- Revenue Optics Ignites AI Revolution in Industrial Distribution
- Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development
- Axiros North America Announces New CEO: Gabriel Davidov
- CCHR Exposes Harms Behind Today's Mental Health Awareness Campaigns
- Now Is the Right Time: Kaltra Highlights Its Proven Replacement Microchannel Coils
- How to Optimize Your Website for AI Search with DeepRank AI
- New Free Science Bingo Cards Help Grade 1 Students Learn Through Play
- DeployHub Joins Catalyst Campus SDA TAP Lab
- Veterans Day 2025: Virginia Veterans Can Claim Free Words of Veterans Book Vouchers
- Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- The AI CEO Partners with D3 Hockey News to Elevate the Voice of Division III Hockey Nationwide
- Statement from the Campaign of Theodis Daniel, Republican for U.S. Congress (TX-18)
- Divine Punk Announces Happy Christmas, a Holiday Soundscape by Rebecca Noelle
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
